

06.30.2014
INTERIM REPORT

PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

CONTENT

HIGHLIGHTS / KEY GROUP FIGURES AT A GLANCE	03
LETTER FROM THE BOARD OF MANAGEMENT	04
INTERIM GROUP MANAGEMENT REPORT	06
CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2014	11
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD FROM APRIL 1 TO JUNE 30, 2014	13
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD FROM JANUARY 1 TO JUNE 30, 2014	14
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD FROM JANUARY 1 TO JUNE 30, 2014	15
CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD FROM JANUARY 1 TO JUNE 30, 2014	17
NOTES TO THE GROUP INTERIM REPORT FOR THE PERIOD FROM JANUARY 1 TO JUNE 30, 2014	18
ADDITIONAL INFORMATION	23

HIGHLIGHTS

Sales of €69.1 million in 6M/2014
(+14.9%; 6M/2013: €60.1 million)

EBIT margin of 16.3%² in 6M/2014
(+260 basis points; 6M/2013: 13.7%)

EBIT of € 11.2 million² in 6M/2014
(+36.0%; 6M/2013: €8.3 million)

Consolidated net income of €9.6 million² in 6M/2014
(+47.3%; 6M/2013: €6.5 million)

Earnings per share of €0.82² in 6M/2014
(+46.4%; 6M/2013: €0.56)

KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01. - 06.30.2014	01.01. - 06.30.2013 ¹	Change
Sales	69,050	60,071	+14.9 %
EBIT	11,232 ²	8,257	+36.0 %
EBIT margin (%)	16.3 ²	13.7	+260 BPS
Consolidated net income	9,635 ²	6,543	+47.3 %
Earnings per share (€)	0.82 ²	0.56	+46.4 %
No. of employees (06.30.)	546	543	+0.6 %

in € thousands	06.30.2014	12.31.2013 ¹	Change
Shareholders' equity	100,170	97,179	+3.1 %
Total assets	124,992	117,788	+6.1 %
Equity ratio (%)	80.1	82.5	-240 BPS

¹ The accounting methods used in the consolidated financial statements were amended in line with IAS 8 in the 2013 financial year. Reference is made in this respect to the information in the 2013 Annual Report in Section A of the notes to the consolidated financial statements.

² 2014 figure adjusted to exclude a one-off item resulting from recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. Unadjusted EBIT amounts to € 10.3 million, the corresponding EBIT margin amounts to 14.9%, consolidated net income to € 8.9 million and earnings per share to € 0.76. The effective amount of the liability due may differ at the time of payment.

LETTER FROM THE BOARD OF MANAGEMENT

Dear Shareholders,

We can look back on a solid first half of 2014 in which we generated substantial sales growth while at the same time significantly raising our EBIT margin.

We boosted our sales for the first six months by 14.9% to €69.1 million. The adjusted EBIT margin rose to 16.3%, up from 13.7% in the equivalent period in the prior year. Adjusted earnings per share increased by 46.4% to €0.82.


Even though we view this development as a normalization in our margin performance and although we expect the company to post healthy developments in the second half of the year, we are not yet in a position to announce the end of the temporary weakness seen in capacity utilization levels in terms of customer test volumes. Given stocking and order processes, we are still witnessing fluctuations within quarters. Extreme fluctuations, such as those at the end of 2012, have not reoccurred since and the strong second quarter gives us reason to expect a further normalization in the service parts business. Based on information currently available, we expect to see positive developments in terms of our sales and earnings performance in the second half of the year as well.

Although there was little to report in terms of significant newsflow during the quarter, the company's operating performance was nevertheless consistently positive. Major development projects are running on schedule and further market launches by our customers are pending. These will gradually contribute to our expected sales growth in the coming quarters. Furthermore, an increase in the dividend to a new record level was approved at the Annual General Meeting.

In 2015 we will be further expanding our existing development and production capacities, most recently extended in 2010. Planning work for these measures has begun and we will keep you informed. Specifically, we are currently planning the construction of a proprietary development building in Romania. Driven not least by the successful conclusion of further development orders currently in negotiation and our planned capacity expansion measures, we intend to uphold our growth both throughout and beyond the forecast period.

Birkenfeld, July 2014

The Board of Management of
STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Dr. Claus Vielsack

INTERIM GROUP MANAGEMENT REPORT

REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

Sales grew by 14.9% to €69.1 million in the first six months of the 2014 financial year (previous year: €60.1 million). The gross profit (gross profit on sales) increased to €22.6 million (32.7% of sales), up €3.1 million on the previous year's figure of €19.5 million (32.5% of sales). This was due to significant growth in the volume of established analyzer systems and the ongoing slightly positive development in turnover with service parts.

Gross development expenses rose by €0.7 million to €10.6 million, of which €7.7 million were capitalized. Sales-related expenses could be further significantly reduced from €4.3 million to €3.0 million. Administration expenses increased by €1.1 million to €5.8 million. This was chiefly due to the recognition of expenses for the remaining years covered by the residual term of the management board contract for a retired member of the Board of Management.

Due to a higher volume of earnings-neutral development sales, depreciation and amortization rose from €2.9 million to €3.6 million. At €10.3 million, EBIT improved by 24.4% and significantly exceeded the previous year's figure, and that despite the one-off charge due to the expenses incurred for changes in the Board of Management. The figures include a small positive financial effect, one set also to continue over the remaining quarters of the current financial year, resulting from the termination of a development and supply agreement announced in July 2013. Based on current planning, this monetary item will increase the EBIT margin for the 2014 financial year as a whole by around 30 basis points. The EBIT margin thus amounted to 14.9% (adjusted: 16.3%; previous year: 13.7%). As in the previous year, net financial expenses were marginally negative. The tax result amounted to €1.3 million. STRATEC can therefore report a 36.4% increase in consolidated net income to €8.9 million for the period under report (previous year: €6.5 million). Earnings per share amounted to €0.76 (previous year: €0.56).

Despite ongoing strong demand for analyzer systems and a full development pipeline, inventories only rose slightly from €18.1 million to €18.9 million. Due to the significant reduction in trade receivables, total receivables could be reduced by €0.6 million.

The equity ratio amounted to 80.1%. The Group has reduced its non-current financial liabilities by €1.0 million to €5.6 million. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Other current liabilities also include the liability for the remaining years covered by the residual term of the management board contract for a retired member of the Board of Management.

The cash flow from operating activities rose significantly from €13.5 million in the previous year to €17.1 million. At €3.9 million, investments fell short of the previous year's figure. Despite the dividend payment, cash and cash equivalents thus increased from €20.7 million to €27.1 million.

CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

The Ukraine crisis has overshadowed the growth forecast issued by the International Monetary Fund (IMF) for the global economy. In its global economic outlook issued in April, the IMF forecast robust growth in economic output, but warned at the same time of "new geopolitical risks" due to the conflict between Kiev and Moscow. The IMF saw the industrialized economies, above all the USA, as anchors of global growth. The economies of core euro area states were also recovering. The upturn in crisis-hit countries such as Spain, Portugal, and Greece nevertheless remained fragile. According to the IMF, emerging economies still accounted for more than two thirds of global economic growth, but recent developments here had tended to be disappointing. The Chinese economy had cooled slightly compared with 2013. The IMF nevertheless expected the world's second-largest economy to post strong growth of 7.5% this year.

Global economic growth had strengthened in the second half of 2013 and was set to improve further in 2014 and 2015. Following growth of 3% in the past year, the IMF had forecast an increase of 3.6% in global economic output in 2014. This should be followed by global economic growth of 3.9% in 2015.

Having said this, the monetary fund has cut back its growth expectations for the global economy by 0.1 percentage points compared with its previous outlook in January. Alongside flagging developments in emerging economies, IMF experts have also factored the potential implications of the Ukraine crisis into their current global economic outlook. Given the threat of western sanctions, they have cut this year's growth forecast for the Russian economy from 1.9% to 1.3%. Any further escalation "could have substantially negative effects for the region through both financial and trading channels".

The company has not yet witnessed any implications from current events in connection with the Ukraine crisis and sanctions against Russia. Our partners, who generally market our systems with their own reagents, have currently reported only a very low level of impact.

Irrespective of the aforementioned developments, global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications for STRATEC.

REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

In the current year, STRATEC is focusing on achieving further major development milestones, additional market launches, and finalizing negotiations for new development and production contracts. Furthermore, the expansion in the company's production and development capacities is set to play a key role in 2014. One example here is planned construction work at the Romanian location where, depending on the relevant permits being issued, construction work should begin before the end of the current financial year.

For 2014, STRATEC continues to expect substantial sales growth compared with the 2013 financial year accompanied by a slight increase in the EBIT margin. The medium-term financial forecast for the years through to 2017 provides for average annual sales growth of 8% to 12% based on the volume of sales generated in the 2013 financial year.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on April 15, 2014 upon the compilation of the Annual Report for the 2013 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2013 financial year dated April 15, 2014. Details of our risk management system and our company's specific opportunity and risk profile can be found in the "Opportunity and Risk Report" section of our 2013 Group Management Report. Information about our use of financial instruments can be found in Section F of the 2013 Group Management Report.

CONSOLIDATED BALANCE SHEET

as of June 30, 2014
of STRATEC Biomedical AG

ASSETS

in € thousands	06.30.2014	12.31.2013	01.01.2013 ¹
NON-CURRENT ASSETS			
Goodwill	4,481	4,427	4,547
Other intangible assets	26,563	25,761	22,280
Property, plant and equipment	16,609	17,013	17,108
Interests in associates	404	392	363
Deferred tax assets	828	867	2,135
	48,885	48,460	46,433
CURRENT ASSETS			
Raw materials and supplies	10,355	8,391	8,857
Unfinished products, unfinished services	6,092	7,758	7,846
Finished products and goods	2,485	1,942	807
Trade receivables	19,516	23,372	25,627
Future receivables from construction contracts	1,286	1,312	1,011
Receivables from associates	69	65	96
Income tax receivables	6,001	3,523	2,016
Other receivables and other assets	2,433	1,585	2,182
Other financial assets	723	646	366
Cash and cash equivalents	27,147	20,734	13,209
	76,107	69,328	62,017
TOTAL ASSETS	124,992	117,788	108,450

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

SHAREHOLDERS' EQUITY AND DEBT

in € thousands

	<u>06.30.2014</u>	12.31.2013	01.01.2013 ¹
SHAREHOLDERS' EQUITY			
Share capital	11,791	11,770	11,738
Capital reserve	17,919	17,219	16,247
Revenue reserves	69,635	67,766	58,768
Other equity	825	424	789
	100,170	97,179	87,542
DEBT			
NON-CURRENT DEBT			
Non-current financial liabilities	5,603	6,643	7,459
Pension provisions	14	14	28
Deferred taxes	1,659	1,389	1,604
	7,276	8,046	9,091
CURRENT DEBT			
Current financial liabilities	2,209	1,895	1,183
Trade payables	6,275	4,402	4,288
Liabilities to associates	205	211	282
Other current liabilities	6,634	4,520	5,218
Current provisions	684	679	608
Income tax liabilities	1,539	857	238
	17,546	12,563	11,817
TOTAL SHAREHOLDERS' EQUITY AND DEBT	<u>124,992</u>	117,788	108,450

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from April 1 to June 30, 2014
of STRATEC Biomedical AG

in € thousands	04.01.-06.30.2014	04.01.-06.30.2013 ¹
SALES	34,680	29,786
Cost of sales	-23,327	-20,746
Gross profit	11,353	9,040
Research and development expenses	-1,545	-738
Information only: Total research and development expenses	-4,889	-5,076
Information only: Capitalized research and development expenses	3,344	4,338
Sales-related expenses	-1,322	-2,086
General administrative expenses	-2,302	-2,329
Other operating expenses	-278	-41
EBIT	5,906	3,846
Net financial expenses	2	-97
Earnings before taxes (EBT)	5,908	3,749
Current tax expenses	-513	-254
Deferred tax expenses	-132	-570
Consolidated net income	5,263	2,925
Items that may be subsequently reclassified to profit or loss		
Currency translation differences from translation of foreign operations	247	-381
COMPREHENSIVE INCOME	5,510	2,544
Earnings per share in €	0.45	0.25
No. of shares used as basis	11,759,486	11,727,142
Earnings per share, diluted, in €	0.45	0.25
No. of shares used as basis, diluted	11,812,079	11,767,479

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to June 30, 2014
of STRATEC Biomedical AG

in € thousands	01.01.-06.30.2014	01.01.-06.30.2013 ¹
SALES	69,050	60,071
Cost of sales	-46,466	-40,574
Gross profit	22,584	19,497
Research and development expenses	-2,947	-2,010
Information only: Total research and development expenses	-10,627	-9,945
Information only: Capitalized research and development expenses	7,680	7,935
Sales-related expenses	-2,997	-4,270
General administrative expenses	-5,810	-4,672
Other operating expenses	-556	-288
EBIT	10,274	8,257
Net financial expenses	-79	-169
Earnings before taxes (EBT)	10,195	8,088
Current tax expenses	-969	-479
Deferred tax expenses	-302	-1,066
Consolidated net income	8,924	6,543
Items that may be subsequently reclassified to profit or loss		
Currency translation differences from translation of foreign operations	401	-407
COMPREHENSIVE INCOME	9,325	6,136
Earnings per share in €	0.76	0.56
No. of shares used as basis	11,758,754	11,726,332
Earnings per share, diluted, in €	0.76	0.56
No. of shares used as basis, diluted	11,803,859	11,771,823

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the Period from January 1 to June 30, 2013
of STRATEC Biomedical AG

in € thousands	Share capital	Capital reserve
Balance at 01.01.2013 ¹	11,738	16,247
Equity transactions with owners		
Dividend payment		
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	10	184
Allocations due to stock option plans		88
Total comprehensive income		
Change in scope of consolidation		4
Balance at 06.30.2013	11,748	16,523

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

for the Period from January 1 to June 30, 2014
of STRATEC Biomedical AG

in € thousands	Share capital	Capital reserve
Balance at 01.01.2014	11,770	17,219
Equity transactions with owners		
Dividend payment		
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	21	544
Allocations due to stock option plans		156
Total comprehensive income		
Balance at 06.30.2014	11,791	17,919

Revenue reserves		Other equity				
Accumulated net income	Free revenue reserves	Treasury stock	Pension plans	Currency translation		Group equity
39,376	19,392	-212	-32	1,033		87,542
-6,567						-6,567
						194
						88
6,543				-407		6,136
86						90
39,438	19,392	-212	-32	626		87,483

Revenue reserves		Other equity				
Accumulated net income	Free revenue reserves	Treasury stock	Pension plans	Currency translation		Group equity
48,374	19,392	-212	-18	654		97,179
-7,055						-7,055
						565
						156
8,924				401		9,325
50,243	19,392	-212	-18	1,055		100,170

CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to June 30, 2014
of STARTEC Biomedical AG

in € thousands	01.01.-06.30.2014	01.01.-06.30.2013 ¹
Consolidated net income (after taxes)	8,924	6,543
Depreciation and amortization	3,588	2,909
Current income tax expenses	969	479
Income taxes paid less income taxes received	-2,774	-2,370
Financial income	-61	-69
Financial expenses	100	238
Interest paid	-97	-231
Interest received	61	42
Other non-cash expenses	218	251
Other non-cash income	-584	-293
Cash flow	10,344	7,499
Change in deferred taxes through profit or loss	302	1,066
Profit on disposals of non-current assets	-1	-6
Decrease in inventories, trade receivables and other assets	2,339	4,219
Increase in trade payables and other liabilities	4,077	728
Inflow of funds from operating activities	17,061	13,506
Incoming payments from disposals of non-current assets		
Property, plant and equipment	1	6
Outgoing payments for investments in non-current assets		
Intangible assets	-3,048	-4,378
Property, plant and equipment	-858	-1,249
Outgoing payments for acquisitions of consolidated companies	0	-127
Outflow of funds for investing activities	-3,905	-5,748
Outgoing payments for repayment of financial liabilities	-747	-288
Incoming payments for issues of shares for employee stock option programs	565	194
Dividend payment	-7,055	-6,567
Outflow of funds for financing activities	-7,237	-6,661
Cash-effective change in cash and cash equivalents	5,919	1,097
Cash and cash equivalents at start of period	20,734	13,209
Change in scope of consolidation	0	84
Impact of exchange rate movements	494	-258
Cash and cash equivalents at end of period	27,147	14,132

¹ Previous year's figures adjusted in line with the information provided in the notes to the consolidated financial statements in the 2013 Annual Report (A. General disclosures).

NOTES TO THE GROUP INTERIM REPORT

for the period from January 1 to June 30, 2014
of STRATEC Biomedical AG

SUMMARY OF PRINCIPAL ACCOUNTING AND VALUATION METHODS

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2013 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of June 30, 2014, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2013 financial year.

Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of June 30, 2014.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2013 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€thousand).

ADJUSTMENT TO PREVIOUS YEAR'S FIGURES PURSUANT TO IAS 8

At the end of the 2013 financial year, the accounting methods used to recognize projects were voluntarily adjusted in order to implement recommendations made by the German Financial Reporting Enforcement Panel (DPR). Moreover, the presentation of shareholders' equity and of the statement of changes in equity were also voluntarily amended and errors were corrected. Further details and a presentation of the overall implications can be found on Pages 48 to 53 of our consolidated financial statements as of December 31, 2013. To ensure comparability, the figures reported for January 1, 2013 and for the period from January 1, 2013 to June 30, 2013 have been adjusted accordingly.

SEGMENT DISCLOSURES

There have been no changes in segmentation compared with the consolidated financial statements as of December 31, 2013.

Segment data by operating segment for the period from January 1 to June 30, 2014

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	71,258	3,537	-5,745	69,050
EBIT	10,289	43	-58	10,274
Assets	135,357	6,678	-17,043	124,992

Segment data by operating segment for the period from January 1 to June 30, 2013

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	62,167	2,071	-4,167	60,071
EBIT	8,978	-453	-437	8,088
Assets	126,441	4,345	-21,860	108,926

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - June 2014	8,361	29,187	31,502	69,050
	12.1 %	45.6 %	42.3 %	100.0 %

in € thousands	Germany	EU	Other	Total
January - June 2013	10,203	26,376	23,492	60,071
	17.0 %	43.9 %	39.1 %	100.0 %

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses not fulfilling the capitalization criteria set out in IAS 38 (Intangible Assets) amounted to €2.9 million in the first six months of the 2014 financial year (previous year: €2.0 million) and mainly involve personnel and material expenses. The STRATEC Group invested a total of €10.6 million in research and development in the first six months of the 2014 financial year (previous year: €9.9 million).

SHAREHOLDERS' EQUITY

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 15 and 16.

The number of ordinary shares with a nominal value of €1.00 each issued by STRATEC AG as of June 30, 2014, amounts to 11,790,945. These are all bearer shares.

DISCLOSURES ON THE VOLUME OF TREASURY STOCK AND ON SUBSCRIPTION RIGHTS HELD BY MEMBERS OF THE COMPANY'S EXECUTIVE AND SUPERVISORY BODIES AND ITS EMPLOYEES PURSUANT TO § 160 (1) NOS. 2 AND 5 OF THE GERMAN STOCK CORPORATION ACT (AKTG)

STRATEC AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of €12,223.00 of the company's share capital and to a 0.10% share of its equity.

Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	Board of Management / Managing Directors	Employees	Total
Outstanding on 01.01.2014	148,500	92,100	240,600
Issued	40,000	9,050	49,050
Exercised	15,000	5,700	20,700
Lapsed	0	0	0
Forfeited	0	0	0
Outstanding on 06.30.2014	173,500	95,450	268,950

Of the stock options granted in the first six months, 40,000 (previous year: 0) were granted to members of the Board of Management (previous year: 0), as in the previous year 0 to managing directors of subsidiaries, and 9,050 (previous year: 23,550) to employees.

Furthermore, members of the Board of Management exercised 15,000 stock option rights in the first six months (previous year: 0). As in the previous year, managing directors of subsidiaries did not exercise any stock option rights in this period. Employees exercised 5,700 stock option rights (previous year: 10,000). To service the stock option rights exercised, a total of 20,700 shares were created from conditional capital (previous year: 10,000).

As in the previous year, no stock option rights lapsed in the period under report.

Furthermore, no stock options rights were forfeited for managing directors or employees (previous year: 2,000 for each category).

EMPLOYEES

Including temporary employees the STRATEC Group had a total workforce of 546 employees as of June 30, 2014 (previous year: 543).

MAJOR EVENTS AFTER THE INTERIM REPORTING DATE

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

RESPONSIBILITY STATEMENT

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

ADDITIONAL INFORMATION

FINANCIAL CALENDAR

July 23, 2014	Interim Report as of June 30, 2014
October 22, 2014	Interim Report as of September 30, 2014
November 2014	German Equity Forum, Frankfurt / Main, Germany - Analysts' conference -

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2014:

September 2014	11 th Annual Goldman Sachs European Medtech and Healthcare Services Conference, London, UK Berenberg Bank & Goldman Sachs German Corporate Conference, Munich, Germany
November 2014	HSBC Healthcare Day 2014, Frankfurt / Main, Germany Jefferies 2014 Global Healthcare Conference, London, UK
December 2014	Berenberg Bank European Conference, Pennyhill Park, UK

Partially incomplete / subject to amendment

ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at www.stratec.com.

IMPRINT

Published by

STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0
Fax: +49 7082 7916-999
info@stratec.com
www.stratec.com

Investor Relations

ANDREAS KÜNZEL
Phone: +49 7082 7916-185
Fax: +49 7082 7916-999
a.kuenzel@stratec.com

Corporate Communications

ANDRE LOY
Phone: +49 7082 7916-190
Fax: +49 7082 7916-999
a.loy@stratec.com

NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

STRATEC BIOMEDICAL AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

info@stratec.com

www.stratec.com

